<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Myriad Genetics Inc — News on 6ix</title>
<link>https://6ix.com/company/myriad-genetics-inc</link>
<description>Latest news and press releases for Myriad Genetics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/myriad-genetics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a01878dffbe2df108bf8.webp</url>
<title>Myriad Genetics Inc</title>
<link>https://6ix.com/company/myriad-genetics-inc</link>
</image>
<item>
<title>Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-to-release-first-quarter-2026-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-to-release-first-quarter-2026-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 28 Apr 2026 20:05:00 GMT</pubDate>
<description>SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first quarter of 2026. A live webc</description>
</item>
<item>
<title>Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026</guid>
<pubDate>Thu, 16 Apr 2026 13:15:00 GMT</pubDate>
<description>SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026. "AACR is one of the premier forums for oncology research, and we are excited to share the depth of work underway across our MRD and hereditary cancer programs, including two podium presentat</description>
</item>
<item>
<title>Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-expands-access-for-mychoice-test-to-prostate-cancer-patients-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-expands-access-for-mychoice-test-to-prostate-cancer-patients-in-japan</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine,</description>
</item>
<item>
<title>Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-underscores-commitment-to-cancer-care-continuum-with-new-data-presentations-at-sgo-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-underscores-commitment-to-cancer-care-continuum-with-new-data-presentations-at-sgo-annual-meeting</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine,</description>
</item>
<item>
<title>Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-receives-fda-approval-of-the-mychoice-cdx-test-as-the-companion-diagnostic-for-zejula-niraparib-for-patients-with-ovarian-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-receives-fda-approval-of-the-mychoice-cdx-test-as-the-companion-diagnostic-for-zejula-niraparib-for-patients-with-ovarian-cancer-1</guid>
<pubDate>Tue, 17 Mar 2026 20:05:00 GMT</pubDate>
<description>Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United StatesSALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inh</description>
</item>
<item>
<title>Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer </title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-receives-fda-approval-of-the-mychoice-cdx-test-as-the-companion-diagnostic-for-zejula-niraparib-for-patients-with-ovarian-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-receives-fda-approval-of-the-mychoice-cdx-test-as-the-companion-diagnostic-for-zejula-niraparib-for-patients-with-ovarian-cancer</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in</description>
</item>
<item>
<title>Myriad Commercially Launches Precise MRD with Select Community Oncologists</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-commercially-launches-precise-mrd-with-select-community-oncologists</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-commercially-launches-precise-mrd-with-select-community-oncologists</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>Launch Represents Significant Step to Broader CommercializationSALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide</description>
</item>
<item>
<title>Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/six-presented-abstracts-at-asco-gu-2026-reinforce-the-clinical-impact-of-myriads-precise-mrd-prolaris-and-myrisk-tests</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/six-presented-abstracts-at-asco-gu-2026-reinforce-the-clinical-impact-of-myriads-precise-mrd-prolaris-and-myrisk-tests</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will</description>
</item>
<item>
<title>Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-reports-fourth-quarter-and-full-year-2025-financial-results-reiterates-2026-financial-guidance-reflecting-strengthened-execution</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-reports-fourth-quarter-and-full-year-2025-financial-results-reiterates-2026-financial-guidance-reflecting-strengthened-execution</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9</description>
</item>
<item>
<title>FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/firstgene-study-demonstrates-high-analytical-sensitivity-and-specificity-for-each-component-of-the-test</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/firstgene-study-demonstrates-high-analytical-sensitivity-and-specificity-for-each-component-of-the-test</guid>
<pubDate>Thu, 19 Feb 2026 14:15:00 GMT</pubDate>
<description>Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical ChemistrySALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the FirstGene® Multiple Prenatal Screen in Clinical Chemistry. The study showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA scree</description>
</item>
<item>
<title>Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-release-fourth-quarter-211500302</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-release-fourth-quarter-211500302</guid>
<pubDate>Mon, 16 Feb 2026 21:15:00 GMT</pubDate>
<description>Management will participate in three upcoming investor healthcare conferencesSALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and busines</description>
</item>
<item>
<title>Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-advances-mrd-commercialization-timeline-135000934</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-advances-mrd-commercialization-timeline-135000934</guid>
<pubDate>Tue, 27 Jan 2026 13:50:00 GMT</pubDate>
<description>Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad</description>
</item>
<item>
<title>Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-announces-select-preliminary-133000284</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-announces-select-preliminary-133000284</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at inve</description>
</item>
<item>
<title>Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today</description>
</item>
<item>
<title>Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-present-8-abstracts-about-mrd-and-other-studies-2025-san-antonio</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-present-8-abstracts-about-mrd-and-other-studies-2025-san-antonio</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE</description>
</item>
<item>
<title>Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/clairity-myriad-genetics-and-magview-launch-the-first-integrated-ai-and-genetic-risk-platform-for-personalized-breast-health</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/clairity-myriad-genetics-and-magview-launch-the-first-integrated-ai-and-genetic-risk-platform-for-personalized-breast-health</guid>
<pubDate>Tue, 25 Nov 2025 21:15:00 GMT</pubDate>
<description>Actionable offering helps enable earlier, more personalized breast cancer interventionsBOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leade</description>
</item>
<item>
<title>Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-participate-upcoming-investor-healthcare-conferences-2025-11-11</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-participate-upcoming-investor-healthcare-conferences-2025-11-11</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today</description>
</item>
<item>
<title>Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-adds-15-clinically-actionable-genes-myriskr-hereditary-cancer-test</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-adds-15-clinically-actionable-genes-myriskr-hereditary-cancer-test</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad</description>
</item>
<item>
<title>Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-highlight-genetic-testing-advancements-2025-national-society-genetic</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-highlight-genetic-testing-advancements-2025-national-society-genetic</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine,</description>
</item>
<item>
<title>Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution</title>
<link>https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-reports-third-quarter-2025-financial-results-reiterates-2025</link>
<guid isPermaLink="true">https://6ix.com/company/myriad-genetics-inc/news/myriad-genetics-reports-third-quarter-2025-financial-results-reiterates-2025</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1</description>
</item>
</channel>
</rss>